KRAS and adenocarcinoma: We were unable to evaluate EGFR/KRAS somatic mutation data for adenocarcinoma subgrouping, as most resections accrued before this was routine somatic mutation clinical testing, and post-hoc subject permission was not possible to obtain for many subjects, due to interval subject deaths, and other factors.